Exploring how carnosine from brain cells affects Alzheimer's disease
Development of new tools to explore the role of oligodendrocyte-derived carnosine in Alzheimer Disease
This study is looking at how a natural substance called carnosine, made by certain brain cells, helps protect the brain from a harmful chemical linked to Alzheimer's disease, and it aims to create special mouse models to see what happens when carnosine levels are lowered.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10887022 on NIH RePORTER |
What this research studies
This research investigates the role of carnosine, a compound produced by specific brain cells called oligodendrocytes, in detoxifying a harmful substance known as acrolein, which is linked to Alzheimer's disease. The study aims to develop genetic mouse models to reduce carnosine levels in the brain, allowing researchers to better understand its impact on aging and the development of Alzheimer's. By examining these models, the research seeks to uncover the mechanisms by which carnosine may protect against the toxic effects of acrolein in the context of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's disease or those in the early stages of cognitive decline.
Not a fit: Patients with advanced Alzheimer's disease or those without any cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance carnosine levels in the brain, potentially slowing or preventing the progression of Alzheimer's disease.
How similar studies have performed: Previous studies have shown promising results in using carnosine supplementation to improve brain function in aging models, suggesting that this approach may hold potential for Alzheimer's treatment.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Elbaz-Eilon, Benayahu — Northwestern University at Chicago
- Study coordinator: Elbaz-Eilon, Benayahu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.